
Current Price | $65.11 | Mkt Cap | $82.0B |
---|---|---|---|
Open | $64.82 | P/E Ratio | 665.39 |
Prev. Close | $65.11 | Div. (Yield) | $2.84 (4.4%) |
Daily Range | $64.24 - $65.25 | Volume | 5,848,292 |
52-Wk Range | $56.56 - $85.79 | Avg. Daily Vol. | 8,013,267 |
A biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.
Current Price | $65.11 | Mkt Cap | $82.0B |
---|---|---|---|
Open | $64.82 | P/E Ratio | 665.39 |
Prev. Close | $65.11 | Div. (Yield) | $2.84 (4.4%) |
Daily Range | $64.24 - $65.25 | Volume | 5,848,292 |
52-Wk Range | $56.56 - $85.79 | Avg. Daily Vol. | 8,013,267 |
The best Bull and Bear pitches based on recency and number of recommendations.
This company has proved that it can cure diseases. It has over $30B in cash. Good mgmt. Good yield. As of today at has a P/E of 7. If this company was not here tomorrow, people would notice.
I have a real hard time imagining that Gilead will have sold enough Remdesivir to make this stock a market performer much less a market *beater.* I do continue to own shares in my real portfolio though, so I'm happy to be proven wrong. Underperform.
Read the most recent pitches from players about GILD.
Recs
Dividends500 tracks the healthiest dividends in the S&P 500.
To qualify for the portfolio, the company must meet three simple requirements:
- Member of the S&P 500
- Payout ratio below 50%
- Dividend growth year over year
Recs
Looks cheap. This company has several projects with positive surprise potential. Also, the stock price fell to a level where it becomes a value pick.
Recs
More data on Remdesivir likely to show it's not very effective; A new administration will undo FDA approval if liver and kidney side effects persist. Increasingly desperate acquisitions at extreme valuations will be hard to generate a return. Finally, the US government is going to take profits or patents related to HIV and hepatitis -- I don't see a way around that severely limiting the company's profit moving forward.
Find the members with the highest scoring picks in GILD.
BrianMotleyFool (72.47) Score: +536.73
The Score Leader is the player with the highest score across all their picks in GILD.
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
WilliamCrook2003 | 72.28 |
|
![]() |
5Y | $13.12 | +396.30% | +207.17% | +189.13 | 1 Comment | |
UrineLuck73 | < 20 | 1/29/2007 |
![]() |
NS | $13.12 | +396.30% | +207.17% | +189.13 | 0 Comment | |
predragj | 42.70 | 1/30/2007 |
![]() |
NS | $13.29 | +390.02% | +206.82% | +183.20 | 0 Comment | |
mxdfool | < 20 | 12/15/2006 |
![]() |
5Y | $13.35 | +387.78% | +205.76% | +182.02 | 0 Comment | |
betsypurcell | < 20 | 1/24/2007 |
![]() |
NS | $13.37 | +387.10% | +205.49% | +181.61 | 0 Comment | |
JSergeant | 75.56 | 7/3/2006 |
![]() |
3Y | $12.42 | +424.07% | +244.01% | +180.06 | 0 Comment | |
rmarinchek | < 20 | 1/25/2007 |
![]() |
3W | $13.47 | +383.45% | +203.64% | +179.81 | 0 Comment | |
Redskins2k9 | < 20 | 1/25/2007 |
![]() |
5Y | $13.47 | +383.45% | +203.64% | +179.81 | 0 Comment | |
opveiby | 78.96 | 1/25/2007 |
![]() |
5Y | $13.47 | +383.45% | +203.64% | +179.81 | 0 Comment | |
jer8899 | 69.55 | 1/23/2007 |
![]() |
NS | $13.44 | +384.51% | +205.53% | +178.98 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.